Sandoz Receives Health Canada’s Approval to Launch Ziextenzo (biosimilar, pegfilgrastim) and Riximyo (biosimilar, rituximab) in Canada

 Sandoz Receives Health Canada’s Approval to Launch Ziextenzo (biosimilar, pegfilgrastim) and Riximyo (biosimilar, rituximab) in Canada

Sandoz’s Erelzi (etanercept, biosimilar) Receives Health Canada Approval for Psoriatic Arthritis (PsA) in Adults

Shots:

  • Health Canada has approved Ziextenzo (a biosimilar referencing Neulasta) and Riximyo (a biosimilar referencing Rituxan) for marketing in Canada
  • Sandoz has received Health Canada’s Notice of Compliance on Apr 21, 2020, for the use of Ziextenzo to reduce the incidence of febrile neutropenia while Riximyo has received approval on Apr 28, 2020 to treat NHL, CLL and RA
  • The approval of Ziextenzo and Riximyo expands Sandoz’s oncology biosimilar portfolio. The approval reinforces Sandoz’ status as the leading biosimilar and generic pharmaceutical company in Canada

Click here to read full press release/ article | Ref: BuinessWire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post